Effect of margin width on local recurrence in triple-negative breast cancer patients treated with breast-conserving therapy

Annals of Surgical Oncology

Volumn 21, Issue 4, 2014, Pages 1209-1214

  Pilewskie, Melissa ^a   Ho, Alice ^a   Orell, Emily ^a   Stempel, Michelle ^a   Chen, Yu ^a   Eaton, Anne ^a   Patil, Sujata ^a   Morrow, Monica ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE;

ADULT; ARTICLE; CANCER RECURRENCE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; PARTIAL MASTECTOMY; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME;

FEMALE; FOLLOW-UP STUDIES; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84896085385     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3416-5     Document Type: Article

References (26)

1. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087-106. (Pubitemid 41797643)
2. Bouganim N, Tsvetkova E, Clemons M, et al. Evolution of sites of recurrence after early breast cancer over the last 20 years: implications for patient care and future research. Breast Cancer Res Treat. 2013;139:603-6.
3. Singletary SE. Surgical margins in patients with early-stage breast cancer treated with breast conservation therapy. Am J Surg. 2002;184:383-93. (Pubitemid 35335942)
4. Azu M, Abrahamse P, Katz SJ, et al. What is an adequate margin for breast-conserving surgery? Surgeon attitudes and correlates. Ann Surg Oncol. 2010;17:558-63.
5. Lovrics PJ, Gordon M, Cornacchi SD, et al. Practice patterns and perceptions of margin status for breast conserving surgery for breast carcinoma: National Survey of Canadian General Surgeons. Breast. 2012;21:730-4.
6. Hassani A, Griffith C, Harvey J. Size does matter: High volume breast surgeons accept smaller excision margins for wide local excision - a national survey of the surgical management of wide local excision margins in UK breast cancer patients. Breast. 2013;22:718-22.
7. Houssami N, Macaskill P, Marinovich ML, et al. Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy. Eur J Cancer. 2010;46:3219-32.
8. Lowery AJ, Kell MR, Glynn RW, et al. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat. 2012;133:831-41.
9. Groot G, Rees H, Pahwa P, et al. Predicting local recurrence following breast-conserving therapy for early stage breast cancer: the significance of a narrow (
10. Chen W, Stroom J, Sonke JJ, et al. Impact of negative margin width on local recurrence in breast conserving therapy. Radiother Oncol. 2012;104:148-54.
11. Hattangadi-Gluth JA, Wo JY, Nguyen PL, et al. Basal subtype of invasive breast cancer is associated with a higher risk of true recurrence after conventional breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2012;82:1185-91.
12. Panoff JE, Hurley J, Takita C, et al. Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation. Breast Cancer Res Treat. 2011;128:899-906.
13. Kim MM, Dawood S, Allen P, et al. Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer. Cancer. 2012;118:4936-43.
14. Russo AL, Arvold ND, Niemierko A, et al. Margin status and the risk of local recurrence in patients with early-stage breast cancer treated with breast-conserving therapy. Breast Cancer Res Treat. 2013;140:353-61.
15. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996;88:1529-42. (Pubitemid 26374506)
16. Fisher B, Dignam J, Mamounas EP, et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol. 1996;14:1982-92.
17. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-84. (Pubitemid 41464706)
18. Dahabreh IJ, Linardou H, Siannis F, et al. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist. 2008;13:620-30. (Pubitemid 351904907)
19. Adkins FC, Gonzalez-Angulo AM, Lei X, et al. Triple-negative breast cancer is not a contraindication for breast conservation. Ann Surg Oncol. 2011;18:3164-73.
20. Parker CC, Ampil F, Burton G, et al. Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer? Surgery. 2010;148:386-91.
21. Zumsteg ZS, Morrow M, Arnold B, et al. Breast-conserving therapy achieves locoregional outcomes comparable to mastectomy in women with T1-2N0 triple-negative breast cancer. Ann Surg Oncol. 2013;20:3469-76.
22. Morrow M, Jagsi R, Alderman AK, et al. Surgeon recommendations and receipt of mastectomy for treatment of breast cancer. JAMA. 2009;302:1551-6.
23. McCahill LE, Single RM, Aiello Bowles EJ, et al. Variability in reexcision following breast conservation surgery. JAMA. 2012;307:467-75.
24. Al-Ghazal SK, Blamey RW, Stewart J, et al. The cosmetic outcome in early breast cancer treated with breast conservation. Eur J Surg Oncol. 1999;25:566-70.
25. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429-34. (Pubitemid 47219710)
26. Pogoda K, Niwinska A, Murawska M, et al. Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. Med Oncol. 2013;30:388.